Arqule Inc (ARQL) 1.74 $ARQL
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 2:52PM CDT
It's probably best to forget Valeant and instead invest in some other drug stocks with a favorable Zacks Rank.
VRX: 23.25 (-0.24), OGXI: 1.02 (+0.02), CPRX: 0.80 (+0.03), ARQL: 1.74 (+0.08), SPPI: 6.75 (-0.04)
The Medicines Co.'s Carbavance Scores in Phase III Study
Arpita Dutt - Zacks Investment Research - Tue Jun 28, 9:45AM CDT
The Medicines Co. (MDCO) intends to file for FDA approval in early 2017.
MDCO: 34.90 (+0.51), ANIP: 56.51 (-1.61), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01)
ArQule (ARQL) Shows Strength: Stock Adds 8% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:25AM CDT
ArQule Inc. (ARQL) moved big last session, as its shares jumped 8% on the day.
ARQL: 1.74 (+0.08), ORPN: 1.67 (+0.08)
ArQule: Advancing a Deep and Diverse Clinical Stage Pipeline
ACCESSWIRE - Mon Jun 20, 4:38AM CDT
NEW YORK, NY / ACCESSWIRE / June 20, 2016 / Rising Tide Equity Research, LLC announced today the release of its Initial Equity Report on ArQule, Inc (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of patients. Their clinical development targets biological pathways implicated in a wide range of cancers and certain non-oncology indications. ArQule's discovery and development efforts are guided by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of their compounds in defined patient populations. The Company's proprietary clinical-stage pipeline consists of four drug candidates, all of which are in targeted patient populations making ArQule a leader among companies their size in precision medicine.
ARQL: 1.74 (+0.08)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 41.89 (+0.53), CPRX: 0.80 (+0.03), SHPG: 188.21 (-1.31), ARQL: 1.74 (+0.08)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01), RPRX: 1.73 (+0.05)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 41.69 (+1.87), JAZZ: 139.88 (+1.40), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08)
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 41.69 (+1.87), INCY: 85.70 (+2.17), ARQL: 1.74 (+0.08), ARIA: 7.51 (+0.17)
ArQule Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Conference call scheduled today at 9:00 a.m. ET
ARQL: 1.74 (+0.08)
Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 188.21 (-1.31), ARQL: 1.74 (+0.08), AEGR: 1.67 (+0.02), KERX: 7.25 (+0.35)
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
GlobeNewswire - Wed Apr 20, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
ARQL: 1.74 (+0.08)
Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), AMAG: 25.19 (-0.18)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), ICPT: 151.73 (+7.98)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.21 (+0.04), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), ICPT: 151.73 (+7.98)
Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 3.21 (+0.04), VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10)
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
GlobeNewswire - Tue Apr 05, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 15 Annual Needham Healthcare Conference on April 12, 2016, at 2:20 p.m. ET at the Westin Grand Central Hotel in New York, New York.
ARQL: 1.74 (+0.08)
Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:20PM CDT
Shares of Keryx Biopharmaceuticals, Inc. (KERX) climbed 8.57% after the company announced positive top-line results from its phase III study on Auryxia (ferric citrate).
ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), KERX: 7.25 (+0.35)
Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), CORT: 6.01 (+0.14)
Forget Valeant, Invest in These Attractive Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Tue Jun 28, 2:52PM CDT
It's probably best to forget Valeant and instead invest in some other drug stocks with a favorable Zacks Rank.
VRX: 23.25 (-0.24), OGXI: 1.02 (+0.02), CPRX: 0.80 (+0.03), ARQL: 1.74 (+0.08), SPPI: 6.75 (-0.04)
The Medicines Co.'s Carbavance Scores in Phase III Study
Arpita Dutt - Zacks Investment Research - Tue Jun 28, 9:45AM CDT
The Medicines Co. (MDCO) intends to file for FDA approval in early 2017.
MDCO: 34.90 (+0.51), ANIP: 56.51 (-1.61), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01)
ArQule (ARQL) Shows Strength: Stock Adds 8% in Session
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:25AM CDT
ArQule Inc. (ARQL) moved big last session, as its shares jumped 8% on the day.
ARQL: 1.74 (+0.08), ORPN: 1.67 (+0.08)
ArQule: Advancing a Deep and Diverse Clinical Stage Pipeline
ACCESSWIRE - Mon Jun 20, 4:38AM CDT
NEW YORK, NY / ACCESSWIRE / June 20, 2016 / Rising Tide Equity Research, LLC announced today the release of its Initial Equity Report on ArQule, Inc (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. ArQule's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of patients. Their clinical development targets biological pathways implicated in a wide range of cancers and certain non-oncology indications. ArQule's discovery and development efforts are guided by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of their compounds in defined patient populations. The Company's proprietary clinical-stage pipeline consists of four drug candidates, all of which are in targeted patient populations making ArQule a leader among companies their size in precision medicine.
ARQL: 1.74 (+0.08)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 41.89 (+0.53), JNJ: 122.85 (+0.34), VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08)
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 2:29PM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 7 cents per share in the first quarter of 2016, which was wider than the year-ago loss of 6 cents but in line with the Zacks Consensus Estimate.
ABT: 41.89 (+0.53), CPRX: 0.80 (+0.03), SHPG: 188.21 (-1.31), ARQL: 1.74 (+0.08)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01), RPRX: 1.73 (+0.05)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 41.69 (+1.87), JAZZ: 139.88 (+1.40), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08)
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 41.69 (+1.87), INCY: 85.70 (+2.17), ARQL: 1.74 (+0.08), ARIA: 7.51 (+0.17)
ArQule Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Conference call scheduled today at 9:00 a.m. ET
ARQL: 1.74 (+0.08)
Keryx (KERX) Q1 Loss in Line, Auryxia Up on Strong Demand (Revised)
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 12:30PM CDT
Keryx Biopharmaceuticals Inc.'s (KERX) first-quarter 2016 loss of 22 cents per share was in line with the Zacks Consensus Estimate.
SHPG: 188.21 (-1.31), ARQL: 1.74 (+0.08), AEGR: 1.67 (+0.02), KERX: 7.25 (+0.35)
ArQule To Report First Quarter 2016 Financial Results On May 4, 2016
GlobeNewswire - Wed Apr 20, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May 4, 2016. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update.
ARQL: 1.74 (+0.08)
Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 10:50AM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has received a notice of default from its debtors.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), AMAG: 25.19 (-0.18)
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), ICPT: 151.73 (+7.98)
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 10:10AM CDT
Shares of Intercept Pharmaceuticals, Inc. (ICPT) surged 13.3% just before the FDA Gastrointestinal Drug Advisory Committee's (GIDAC) meeting scheduled for Apr 7, 2016.
ECYT: 3.21 (+0.04), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), ICPT: 151.73 (+7.98)
Valeant Completes Accounting Review of Philidor, Shares Up
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:30AM CDT
Valeant Pharmaceuticals (VRX) announced that an accounting review related to Philidor, which was undertaken by the ad hoc committee appointed by the board of directors, has been completed witth no additional restatements required.
ECYT: 3.21 (+0.04), VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10)
ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
GlobeNewswire - Tue Apr 05, 6:30AM CDT
ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 15 Annual Needham Healthcare Conference on April 12, 2016, at 2:20 p.m. ET at the Westin Grand Central Hotel in New York, New York.
ARQL: 1.74 (+0.08)
Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:20PM CDT
Shares of Keryx Biopharmaceuticals, Inc. (KERX) climbed 8.57% after the company announced positive top-line results from its phase III study on Auryxia (ferric citrate).
ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), KERX: 7.25 (+0.35)
Valeant CEO Gets Subpoena from Senate Aging Committee
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:45PM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) dropped 7.2% after the company's CEO received a subpoena from the Senate Aging Committee amid the ongoing mess.
VRX: 23.25 (-0.24), ARQL: 1.74 (+0.08), SCMP: 11.49 (+0.10), CORT: 6.01 (+0.14)
